SEARCH

SEARCH BY CITATION

References

  • Aapro, M., Scherhag, A. & Burger, H.U. (2008) Effect of treatment with epoetin-β on survival, tumour progression and thromboembolic events in patients with cancer: an updated meta-analysis of 12 randomised controlled studies including 2301 patients. British Journal of Cancer, 99, 1422.
  • Acs, G., Acs, P., Beckwith, S.M., Pitts, R.L., Clements, E., Wong, K. & Verma, A. (2001) Erythropoietin and erythropoietin receptor expression in human cancer. Cancer Research, 61, 35613565.
  • Acs, G., Zhang, P.J., McGrath, C.M., Acs, P., McBroom, J., Mohyeldin, A., Liu, S., Lu, H. & Verma, A. (2003) Hypoxia-inducible erythropoietin signaling in squamous dysplasia and squamous cell carcinoma of the uterine cervix and its potential role in cervical carcinogenesis and tumor progression. American Journal of Pathology, 162, 17891806.
  • Andratschke, N., Schnaiter, A., Weber, W.A., Cai, L., Schill, S., Wiedenmann, N., Schwaiger, M., Molls, M. & Nieder, C. (2006) Preclinical evaluation of erythropoietin administration in a model of radiation-induced kidney dysfunction. International Journal of Radiation Oncology, Biology, Physics, 64, 15131518.
  • Arcasoy, M.O. (2008) The non-haematopoietic biological effects of erythropoietin. British Journal of Haematology, 141, 1431.
  • Bagnis, C., Beaufils, H., Jacquiaud, C., Adabra, Y., Jouanneau, C., Le, N.G., Jaudon, M.C., Bourbouze, R., Jacobs, C. & Deray, G. (2001) Erythropoietin enhances recovery after cisplatin-induced acute renal failure in the rat. Nephrology, Dialysis, Transplantation, 16, 932938.
  • Baz, R., Walker, E., Choueiri, T.K., Abou, J.R., Brand, C., McGowan, B., Yiannaki, E., Andresen, S. & Hussein, M.A. (2007) Recombinant human erythropoietin is associated with increased overall survival in patients with multiple myeloma. Acta Haematologica, 117, 162167.
  • Belenkov, A.I., Shenouda, G., Rizhevskaya, E., Cournoyer, D., Belzile, J.P., Souhami, L., Devic, S. & Chow, T.Y. (2004) Erythropoietin induces cancer cell resistance to ionizing radiation and to cisplatin. Molecular Cancer Therapy, 3, 15251532.
  • Bennett, C.L., Angelotta, C., Yarnold, P.R., Evens, A.M., Zonder, J.A., Raisch, D.W. & Richardson, P. (2006) Thalidomide- and lenalidomide-associated thromboembolism among patients with cancer. Journal of the American Medical Association, 296, 25582560.
  • Bennett, C.L., Silver, S.M., Djulbegovic, B., Samaras, A.T., Blau, C.A., Gleason, K.J., Barnato, S.E., Elverman, K.M., Courtney, D.M., McKoy, J.M., Edwards, B.J., Tigue, C.C., Raisch, D.W., Yarnold, P.R., Dorr, D.A., Kuzel, T.M., Tallman, M.S., Trifilio, S.M., West, D.P., Lai, S.Y. & Henke, M. (2008) Venous thromboembolism and mortality associated with recombinant erythropoietin and darbepoetin administration for the treatment of cancer-associated anemia. Journal of the American Medical Association, 299, 914924.
  • Besarab, A., Bolton, W.K., Browne, J.K., Egrie, J.C., Nissenson, A.R., Okamoto, D.M., Schwab, S.J. & Goodkin, D.A. (1998) The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. New England Journal of Medicine, 339, 584590.
  • Bianchi, R., Buyukakilli, B., Brines, M., Savino, C., Cavaletti, G., Oggioni, N., Lauria, G., Borgna, M., Lombardi, R., Cimen, B., Comelekoglu, U., Kanik, A., Tataroglu, C., Cerami, A. & Ghezzi, P. (2004) Erythropoietin both protects from and reverses experimental diabetic neuropathy. Proceedings of the National Academy of Sciences of the United States of America, 101, 823828.
  • Bianchi, R., Brines, M., Lauria, G., Savino, C., Gilardini, A., Nicolini, G., Rodriguez-Menendez, V., Oggioni, N., Canta, A., Penza, P., Lombardi, R., Minoia, C., Ronchi, A., Cerami, A., Ghezzi, P. & Cavaletti, G. (2006) Protective effect of erythropoietin and its carbamylated derivative in experimental Cisplatin peripheral neurotoxicity. Clinical Cancer Research, 12, 26072612.
  • Bittorf, T., Buchse, T., Sasse, T., Jaster, R. & Brock, J. (2001) Activation of the transcription factor NF-kappaB by the erythropoietin receptor: structural requirements and biological significance. Cellular Signalling, 13, 673681.
  • Bohlius, J., Langensiepen, S., Schwarzer, G., Seidenfeld, J., Piper, M., Bennett, C. & Engert, A. (2005) Recombinant human erythropoietin and overall survival in cancer patients: results of a comprehensive meta-analysis. Journal of the National Cancer Institute, 97, 489498.
  • Bohlius, J., Wilson, J., Seidenfeld, J., Piper, M., Schwarzer, G., Sandercock, J., Trelle, S., Weingart, O., Bayliss, S., Brunskill, S., Djulbegovic, B., Benett, C.L., Langensiepen, S., Hyde, C. & Engert, E. (2006) Recombinant human erythropoietins and cancer patients: updated meta-analysis of 57 studies including 9353 patients. Journal of the National Cancer Institute, 98, 708714.
  • Boogaerts, M., Coiffier, B. & Kainz, C. & the Epoetin β QOL Working Group. (2003) Impact of epoetin β on quality of life in patients with malignant disease. British Journal of Cancer, 88, 988995.
  • Bouscary, D., Pene, F., Claessens, Y.E., Muller, O., Chrétien, S., Fontenay-Roupie, M., Gisselbrecht, S., Mayeux, P. & Lacombe, C. (2003) Critical role for PI3-kinase in the control of erythropoietin-induced erythroid progenitor proliferation. Blood, 101, 34363442.
  • Brines, M. & Cerami, A. (2005) Emerging biological roles for erythropoietin in the nervous system. Nature Reviews Neuroscience, 6, 484494.
  • Brines, M., Grasso, G., Fiordaliso, F., Sfacteria, A., Ghezzi, P., Fratelli, M., Latini, R., Xie, Q.W., Smart, J., Su-Rick, C.J., Pobre, E., Diaz, D., Gomez, D., Hand, C., Coleman, T. & Cerami, A. (2004) Erythropoietin mediates tissue protection through an erythropoietin and common beta-subunit heteroreceptor. Proceedings of the National Academy of Sciences of the United States of America, 101, 1490714912.
  • Brown, W.M., Maxwell, P., Graham, A.N.J., Yakkundi, A., Dunlop, E.A., Shi, Z., Johnston, P.G. & Lappin, T.R.J. (2007) Erythropoietin receptor expression in non-small cell lung carcinoma: a question of antibody specificity. Stem Cells, 25, 718722.
  • Calvillo, L., Latini, R., Kajstura, J., Leri, A., Anversa, P., Ghezzi, P., Salio, M., Cerami, A. & Brines, M. (2003) Recombinant human erythropoietin protects the myocardium from ischemia-reperfusion injury and promotes beneficial remodeling. Proceedings of the National Academy of Sciences of the United States of America, 100, 48024806.
  • Carlini, R.G., Reyes, A.A. & Rothstein, M. (1995) Recombinant human erythropoietin stimulates angiogenesis in vitro. Kidney International, 47, 740745.
  • Caro, J.J., Salas, M., Ward, A. & Goss, G. (2001) Anemia as an independent prognostic factor for survival in patients with cancer: a systemic, quantitative review. Cancer, 91, 22142221.
  • Chang, J., Couture, F., Young, S., McWatters, K.L. & Lau, C.Y. (2005) Weekly epoetin alfa maintains hemoglobin, improves quality of life, and reduces transfusion in breast cancer patients receiving chemotherapy. Journal of Clinical Oncology, 23, 25972605.
  • Dammacco, F., Silvestris, F., Castoldi, G.L., Grassi, B., Bernasconi, C., Nadali, G., Perona, G., De Laurenzi, A., Torelli, U., Ascari, E., Rossi Ferrini, P.L., Caligaris-Cappio, F., Pileri, A. & Resegotti, L. (1998) The effectiveness and tolerability of epoetin alfa in patients with multiple myeloma refractory to chemotherapy. International Journal of Clinical and Laboratory Research, 28, 127134.
  • Dammacco, F., Castoldi, G. & Rodjer, S. (2001) Efficacy of epoetin alfa in the treatment of anaemia of multiple myeloma. British Journal of Haematology, 113, 172179.
  • Digicaylioglu, M. & Lipton, S.A. (2001) Erythropoietin-mediated neuroprotection involves cross-talk between Jak2 and NF-kappaB signalling cascades. Nature, 412, 641647.
  • Dunlop, E.A., Percy, M.J., Boland, M.P., Maxwell, A.P. & Lappin, T.R. (2006) Induction of signalling in non-erythroid cells by pharmacological levels of erythropoietin. Neurodegenerative Diseases, 3, 94100.
  • Dunlop, E.A., Maxwell, A.P. & Lappin, T.R. (2007) Impaired downregulation following erythropoietin receptor activation in non-small cell lung carcinoma. Stem Cells, 25, 380384.
  • Dunst, J. (2001) The use of epoetin alfa to increase and maintain hemoglobin levels during radiotherapy. Seminars in Oncology, 28(2 suppl. 8), 4248.
  • Ebert, B.L. & Bunn, H.F. (1999) Regulation of the erythropoietin gene. Blood, 94, 18641877.
  • Ehrenreich, H., Hasselblatt, M., Dembowski, C., Cepek, L., Lewczuk, P., Stiefel, M., Rustenbeck, H.H., Breiter, N., Jacob, S., Knerlich, F., Bohn, M., Poser, W., Ruther, E., Kochen, M., Gefeller, O., Gleiter, C., Wessel, T.C., De, R.M., Itri, L., Prange, H., Cerami, A., Brines, M. & Siren, A.L. (2002) Erythropoietin therapy for acute stroke is both safe and beneficial. Molecular Medicine, 8, 495505.
  • Elliott, S., Busse, L., Bass, M.B., Lu, H., Sarosi, I., Sinclair, A.M., Spahr, C., Um, M., Van, G. & Begley, G. (2006) Anti-Epo receptor antibodies do not predict Epo receptor expression. Blood, 107, 18921895.
  • Fandrey, J. (2004) Oxygen-dependent and tissue-specific regulation of erythropoietin gene expression. The American Journal of Physiology – Regulatory, Integrative and Comparative Physiology, 286, R977R988.
  • Feldman, L., Wang, Y., Rhim, J.S., Bhattacharya, N., Loda, M. & Sytkowski, A.J. (2006) Erythopoietin stimulates growth and STAT5 phosphorylation in human prostate epithelial and prostate cancer cells. Prostate, 66, 135145.
  • Fu, P. & Arcasoy, M.O. (2007) Erythropoietin protects cardiac myocytes against anthracycline-induced apoptosis. Biochemical and Biophysical Research Communications, 354, 372378.
  • Fu, P., Jiang, X. & Arcasoy, M.O. (2009) Constitutively active erythropoietin receptor expression in breast cancer cells promotes cellular proliferation and migration through a MAP-kinase dependent pathway. Biochemical and Biophysical Research Communications, 379, 696701.
  • Grote, T., Yeilding, A.L., Castillo, R., Butler, D., Fishkin, E., Henry, D.H., DeLeo, M., Fink, K. & Sullivan, D.J. (2005) Efficacy and safety analysis of epoetin alfa in patients with small-cell lung cancer: a randomized, double-blind, placebo-controlled trial. Journal of Clinical Oncology, 23, 93779386.
  • Haller, H., Christel, C., Dannenberg, L., Thiele, P., Lindschau, C. & Luft, F.C. (1996) Signal transduction of erythropoietin in endothelial cells. Kidney International, 50, 481488.
  • Hamadmad, S.N. & Hohl, R.J. (2008) Erythropoietin stimulates cancer cell migration and activates RhoA protein through a mitogen-activated protein kinase/extracellular signal-regulated kinase-dependent mechanism. Journal of Pharmacological Experimental Therapy, 324, 12271233.
  • Hamed, S., Barshack, I., Luboshits, G., Wexler, D., Deutsch, V., Keren, G. & George, J. (2006) Erythropoietin improves myocardial performance in doxorubicin-induced cardiomyopathy. European Heart Journal, 27, 18761883.
  • Hardee, M.E., Kirkpatrick, J.P., Shan, S., Snyder, S.A., Vujaskovic, Z., Rabbani, Z.N., Dewhirst, M.W. & Blackwell, K.L. (2005) Human recombinant erythropoietin (rEpo) has no effect on tumour growth or angiogenesis. British Journal of Cancer, 93, 13501355.
  • Hardee, M.E., Arcasoy, M.O., Blackwell, K.L., Kirkpatrick, J.P. & Dewhirst, M.W. (2006) Erythropoietin biology in cancer. Clinical Cancer Research, 12, 332339.
  • Hardee, M.E., Cao, Y., Fu, P., Jiang, X., Zhao, Y., Rabbani, Z.N., Vujaskovic, Z., Dewhirst, M.W. & Arcasoy, M.O. (2007) Erythropoietin blockade inhibits the induction of tumor angiogenesis and progression. PLoS ONE, 2, e549.
  • Haroon, Z.A., Amin, K., Jiang, X. & Arcasoy, M.O. (2003) A novel role for erythropoietin during fibrin-induced wound-healing response. American Journal of Pathology, 163, 9931000.
  • Harrison, L.B., Chadha, M., Hill, R.J., Hu, K. & Shasha, D. (2002) Impact of tumor hypoxia and anemia on radiation therapy outcomes. The Oncologist, 7, 492508.
  • Hedenus, M., Adriansson, M., San Miguel, J., Kramer, M.H., Schipperus, M.R., Juvonen, E., Taylor, K., Belch, A., Altés, A., Martinelli, G., Watson, D., Matcham, J., Rossi, G. & Littlewood, T.J. (2003) Darbepoetin alfa 20000161 Study Group. Efficacy and safety of darbepoetin alfa in anaemic patients with lymphoproliferative malignancies: a randomized, double-blind, placebo-controlled study. British Journal of Haematology, 122, 394403.
  • Hedenus, M., Vansteenkiste, J., Kotasek, D., Austin, M. & Amado, R.G. (2005) Darbepoetin alfa for the treatment of chemotherapy-induced anemia: disease progression and survival analysis from four randomized, double-blind, placebo-controlled trials. Journal of Clinical Oncology, 23, 69416948.
  • Heeschen, C., Aicher, A., Lehmann, R., Fichtlscherer, S., Vasa, M., Urbich, C., Mildner-Rihm, C., Martin, H., Zeiher, A.M. & Dimmeler, S. (2003) Erythropoietin is a potent physiologic stimulus for endothelial progenitor cell mobilization. Blood, 102, 13401346.
  • Henke, M., Laszig, R., Rube, C., Schafer, U., Haase, K.D., Schilcher, B., Mose, S., Beer, K.T., Burger, U., Dougherty, C. & Frommhold, H. (2003) Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomised, double-blind, placebo-controlled trial. Lancet, 362, 12551260.
  • Henke, M., Mattern, D., Pepe, M., Bezay, C., Weissenberger, C., Werner, M. & Pajonk, F. (2006) Do erythropoietin receptors on cancer cells explain unexpected clinical findings? Journal of Clinical Oncology, 24, 47084713.
  • Hortner, M., Nielsch, U., Mayr, L.M., Heinrich, P.C. & Haan, S. (2002) A new high affinity binding site for suppressor of cytokine signaling-3 on the erythropoietin receptor. European Journal of Biochemistry, 269, 25162526.
  • Jeong, J.Y., Feldman, L., Solar, P., Szenajch, J. & Sytkowski, A.J. (2008) Characterization of erythropoietin receptor and erythropoietin expression and function in human ovarian cancer cells. International Journal of Cancer, 122, 274280.
  • Joiner, B., Hirst, V.K., McKeown, S.R., McAleer, J.J. & Hirst, D.G. (1993) The effect of recombinant human erythropoietin treatment on tumour radiosensitivity and cancer-associated anaemia in the mouse. British Journal of Cancer, 68, 720726.
  • Katodritou, E., Verrou, E., Hadjiaggelidou, C., Gastari, V., Laschos, K., Kontovinis, L., Kapetanos, D., Constantinou, N., Terpos, E. & Zervas, K. (2008) Erythropoiesis-stimulating agents are associated with reduced survival in patients with multiple myeloma. American Journal of Hematology, 83, 697701.
  • Kilic, E., Kilic, U., Soliz, J., Bassetti, C.L., Gassmann, M. & Hermann, D.M. (2005) Brain-derived erythropoietin protects from focal cerebral ischemia by dual activation of ERK-1/-2 and Akt pathways. FASEB Journal, 19, 20262028.
  • Klingmuller, U. (1997) The role of tyrosine phosphorylation in proliferation and maturation of erythroid progenitor cells – signals emanating from the erythropoietin receptor. European Journal of Biochemistry, 249, 637647.
  • Klingmuller, U., Lorenz, U., Cantley, L.C., Neel, B.G. & Lodish, H.F. (1995) Specific recruitment of SH-PTP1 to the erythropoietin receptor causes inactivation of JAK2 and termination of proliferative signals. Cell, 80, 729738.
  • Kokhaei, P., Abdalla, A.O., Hansson, L., Mikaelsson, E., Kubbies, M., Haselbeck, A., Jernberg-Wiklund, H., Mellstedt, H. & Osterborg, A. (2007) Expression of erythropoietin receptor and in vitro functional effects of epoetins in B-cell malignancies. Clinical Cancer Research, 13, 35363544.
  • Kumar, S.M., Yu, H., Fong, D., Acs, G. & Xu, X. (2006) Erythropoietin activates the phosphoinositide 3-kinase/Akt pathway in human melanoma cells. Melanoma Research, 16, 275283.
  • Lai, S.Y., Childs, E.E., Xi, S., Coppelli, F.M., Gooding, W.E., Wells, A., Ferris, R.L. & Grandis, J.R. (2005) Erythropoietin-mediated activation of JAK-STAT signaling contributes to cellular invasion in head and neck squamous cell carcinoma. Oncogene, 24, 44424449.
  • LaMontagne, K.R., Butler, J., Marshall, D.J., Tullai, J., Gechtman, Z., Hall, C., Meshaw, A. & Farrell, F.X. (2006) Recombinant epoetins do not stimulate tumor growth in erythropoietin receptor-positive breast carcinoma models. Molecular Cancer Therapy, 5, 347355.
  • Lee, S.H., Li, C., Lim, S.W., Ahn, K.O., Choi, B.S., Kim, Y.S., Moon, I.S., Kim, J., Bang, B.K. & Yang, C.W. (2005) Attenuation of interstitial inflammation and fibrosis by recombinant human erythropoietin in chronic cyclosporine nephropathy. American Journal of Nephrology, 25, 6476.
  • Lester, R.D., Jo, M., Campana, W.M. & Gonias, S.L. (2005) Erythropoietin promotes MCF-7 breast cancer cell migration by an ERK/mitogen-activated protein kinase-dependent pathway and is primarily responsible for the increase in migration observed in hypoxia. Journal of Biological Chemistry, 280, 3927339277.
  • Leyland-Jones, B. BEST investigators and Study Group. (2003) Breast cancer trial with erythropoietin terminated unexpectedly. Lancet Oncology, 4, 459460. (Comment in: Lancet Oncology 2004; 5, 206–207)
  • Leyland-Jones, B., Semiglazov, V., Pawlicki, M., Pienkowski, T., Tjulandin, S., Manikhas, G., Makhson, A., Roth, A., Dodwell, D., Baselga, J., Biakhov, M., Valuckas, K., Voznyi, E., Liu, X. & Vercammen, E. (2005) Maintaining normal hemoglobin levels with epoetin alfa in mainly nonanemic patients with metastatic breast cancer receiving first-line chemotherapy: a survival study. Journal of Clinical Oncology, 23, 59605972.
  • Li, J., Vesey, D.A., Johnson, D.W. & Gobe, G. (2007) Erythropoietin reduces cisplatin-induced apoptosis in renal carcinoma cells via a PKC dependent pathway. Cancer Biological Therapy, 6, 19441950.
  • Lipsic, E., Van Der Meer, P., Voors, A.A., Westenbrink, B.D., Van Den Heuvel, A.F., De Boer, H.C., Van Zonneveld, A.J., Schoemaker, R.G., Van Gilst, W.H., Zijlstra, F. & Van Veldhuisen, D.J. (2006) A single bolus of a long-acting erythropoietin analogue darbepoetin alfa in patients with acute myocardial infarction: a randomized feasibility and safety study. Cardiovascular Drugs and Therapy, 20, 135141.
  • Littlewood, T.J., Bajetta, E., Nortier, J.W., Vercammen, E. & Rapoport, B. (2001) Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: results of a randomized, double-blind, placebo-controlled trial. Journal of Clinical Oncology, 19, 28652874.
  • Liu, W.M., Powles, T., Shamash, J., Propper, D., Oliver, T. & Joel, S. (2004) Effect of haemopoietic growth factors on cancer cell lines and their role in chemosensitivity. Oncogene, 23, 981990.
  • Liu, R., Suzuki, A., Guo, Z., Mizuno, Y. & Urabe, T. (2006) Intrinsic and extrinsic erythropoietin enhances neuroprotection against ischemia and reperfusion injury in vitro. Journal of Neurochemistry, 96, 11011110.
  • Longmore, G.D. (2007) Do cancer cells express functional erythropoietin receptors? New England Journal of Medicine, 356, 2447.
  • Ludwig, H., Van Belle, S., Barrett-Lee, P., Birgegård, G., Bokemeyer, C., Gascón, P., Kosmidis, P., Krzakowski, M., Nortier, J., Olmi, P., Schneider, M. & Schrijvers, D. (2004) The European Cancer Anaemia Survey (ECAS): a large, multinational, prospective survey defining the prevalence, incidence, and treatment of anaemia in cancer patients. European Journal of Cancer, 40, 22932306.
  • Ludwig, H., Anderson, K., Dammacco, F., Hedenus, M., Osterborg, A. & Durie, B. (2008) ESAs not the culprit: more studies required. American Journal of Hematology, 83, 880.
  • Macdougall, I.C. (2005) CERA (Continuous Erythropoietin Receptor Activator): a new erythropoiesis-stimulating agent for the treatment of anemia. Current Hematology Reports, 4, 436440.
  • Van Der Meer, P., Lipsic, E., Henning, R.H., Boddeus, K., Van Der Velden, J., Voors, A.A., Van Veldhuisen, D.J., Van Gilst, W.H. & Schoemaker, R.G. (2005) Erythropoietin induces neovascularization and improves cardiac function in rats with heart failure after myocardial infarction. Journal of the American College of Cardiology, 46, 125133.
  • Melli, G., Jack, C., Lambrinos, G.L., Ringkamp, M. & Hoke, A. (2006) Erythropoietin protects sensory axons against paclitaxel-induced distal degeneration. Neurobiology of Disease, 24, 525530.
  • Menon, M.P., Karur, V., Bogacheva, O., Bogachev, O., Cuetara, B. & Wojchowski, D.M. (2006) Signals for stress erythropoiesis are integrated via an erythropoietin receptor-phosphotyrosine-343-Stat5 axis. Journal of Clinical Investigation, 116, 683694.
  • Mittelman, M., Neumann, D., Peled, A., Kanter, P. & Haran-Ghera, N. (2001) Erythropoietin induces tumor regression and antitumor immune responses in murine myeloma models. Proceedings of the National Academy of Sciences of the United States of America, 98, 51815186.
  • Mittelman, M., Zeidman, A., Kanter, P., Katz, O., Oster, H., Rund, D. & Neumann, D. (2004) Erythropoietin has an anti-myeloma effect – a hypothesis based on a clinical observation supported by animal studies. European Journal of Haematology, 72, 155165.
  • Mohyeldin, A., Lu, H., Dalgard, C., Lai, S.Y., Cohen, N., Acs, G. & Verma, A. (2005) Erythropoietin signaling promotes invasiveness of human head and neck squamous cell carcinoma. Neoplasia, 7, 537543.
  • Moon, C., Krawczyk, M., Paik, D., Lakatta, E.G. & Talan, M.I. (2005) Cardioprotection by recombinant human erythropoietin following acute experimental myocardial infarction: dose response and therapeutic window. Cardiovascular Drugs and Therapy, 19, 243250.
  • Osterborg, A., Brandberg, Y. & Hedenus, M. (2005) Impact of epoetin-β on survival of patients with lymphoproliferative malignancies: long-term follow up of a large randomized study. British Journal of Haematology, 129, 206209.
  • Osterborg, A., Aapro, M., Cornes, P., Haselbeck, A., Hayward, C.R. & Jelkmann, W. (2007) Preclinical studies of erythropoietin receptor expression in tumour cells: impact on clinical use of erythropoietic proteins to correct cancer-related anaemia. European Journal of Cancer, 43, 510519.
  • Overgaard, J., Hoff, C. & Sand, H.H. (2007) Randomized study of the importance of novel erythropoiesis stimulating protein (Aranesp) for the effect of radiotherapy in patients with primary squamous cell carcinoma of the head and neck (HNSCC): the Danish Head and Neck Cancer Group DAHANCA 10 rand. European Journal of Cancer, Suppl, 5, 7.
  • Pirker, R., Ramlau, R.A., Schuette, W., Zatloukal, P., Ferreira, I., Lillie, T. & Vansteenkiste, J.F. (2008) Safety and efficacy of darbepoetin alpha in previously untreated extensive-stage small-cell lung cancer treated with platinum plus etoposide. Journal of Clinical Oncology, 26, 23422349.
  • Prutchi-Sagiv, S., Golishevsky, N., Oster, H.S., Katz, O., Cohen, A., Naparstek, E., Neumann, D. & Mittelman, M. (2006) Erythropoietin treatment in advanced multiple myeloma is associated with improved immunological functions: could it be beneficial in early disease? British Journal of Haematology, 135, 660672.
  • Razzouk, B.I., Hord, J.D., Hockenberry, M., Hinds, P.S., Feusner, J., Williams, D. & Rackoff, W.R. (2006) Double-blind, placebo-controlled study of quality of life, hematologic end points, and safety of weekly epoetin alfa in children with cancer receiving myelosuppressive chemotherapy. Journal of Clinical Oncology, 24, 35833589.
  • Ribatti, D., Presta, M., Vacca, A., Ria, R., Giuliani, R., Dell’Era, P., Nico, B., Roncali, L. & Dammacco, F. (1999) Human erythropoietin induces a pro-angiogenic phenotype in cultured endothelial cells and stimulates neovascularization in vivo. Blood, 93, 26272636.
  • Rizzo, J.D., Somerfield, M.R., Hagerty, K.L., Seidenfeld, J., Bohlius, J., Bennett, C.L., Cella, D.F., Djulbegovic, B., Goode, M.J., Jakubowski, A.A., Rarick, M.U., Regan, D.H. & Lichtin, A.E. (2008) Use of epoetin and darbepoetin in patients with cancer: 2007 American Society of Hematology/American Society of Clinical Oncology clinical practice guideline update. Blood, 111, 2541.
  • Sakanaka, M., Wen, T.C., Matsuda, S., Masuda, S., Morishita, E., Nagao, M. & Sasaki, R. (1998) In vivo evidence that erythropoietin protects neurons from ischemic damage. Proceedings of the National Academy of Sciences of the United States of America, 95, 46354640.
  • Sasaki, A., Yasukawa, H., Shouda, T., Kitamura, T., Dikic, I. & Yoshimura, A. (2000) CIS3/SOCS-3 suppresses erythropoietin (EPO) signaling by binding the EPO receptor and JAK2. Journal of Biological Chemistry, 275, 2933829347.
  • Savonije, J.H., Van Groeningen, C.J., Van Bochove, A., Honkoop, A.H., Van Felius, C.L., Wormhoudt, L.W. & Giaccone, G. (2005) Effects of early intervention with epoetin alfa on transfusion requirement, hemoglobin level and survival during platinum-based chemotherapy: results of a multicenter randomised controlled trial. European Journal of Cancer, 41, 15601569.
  • Sharples, E.J. & Yaqoob, M.M. (2006) Erythropoietin in experimental acute renal failure. Nephron. Experimental Nephrology, 104, e83e88.
  • Shasha, D. (2001) The negative impact of anemia on radiotherapy and chemoradiation outcomes. Seminars in Hematology, 38(Suppl. 7), 815.
  • Shikama, Y., Barber, D.L., D’Andrea, A.D. & Sieff, C.A. (1996) A constitutively activated chimeric cytokine receptor confers factor-independent growth in hematopoietic cell lines. Blood, 88, 455464.
  • Silver, D.F. & Piver, M.S. (1999) Effects of recombinant human erythropoietin on the antitumor effect of cisplatin in SCID mice bearing human ovarian cancer: a possible oxygen effect. Gynecologic Oncology, 73, 280284.
  • Silverberg, D.S., Wexler, D., Blum, M., Iaina, A., Sheps, D., Keren, G. & Schwartz, D. (2005) Erythropoietin in heart failure. Seminars in Nephrology, 25, 397403.
  • Sinclair, A.M., Todd, M.D., Forsythe, K., Knox, S.J., Elliott, S. & Begley, C.G. (2007) Expression and function of erythropoietin receptors in tumors: implications for the use of erythropoiesis-stimulating agents in cancer patients. Cancer, 110, 477488.
  • Sinclair, A.M., Rogers, N., Busse, L., Archibeque, I., Brown, W., Kassner, P.D., Watson, J.E., Arnold, G.E., Nguyen, K.C., Powers, S. & Elliott, S. (2008) Erythropoietin receptor transcription is neither elevated nor predictive of surface expression in human tumour cells. British Journal of Cancer, 98, 10591067.
  • Singh, A.K., Szczech, L., Tang, K.L., Barnhart, H., Sapp, S., Wolfson, M. & Reddan, D. (2006) Correction of anemia with epoetin alfa in chronic kidney disease. New England Journal of Medicine, 355, 20852098.
  • Smith, Jr, R.E., Aapro, M.S., Ludwig, H., Pinter, T., Smakal, M., Ciuleanu, T.E., Chen, L., Lillie, T. & Glaspy, J.A. (2008) Darbepoetin alpha for the treatment of anemia in patients with active cancer not receiving chemotherapy or radiotherapy: results of a phase III, multicenter, randomized, double-blind, placebo-controlled study. Journal of Clinical Oncology, 26, 10401050.
  • Spivak, J.L. (1994) Recombinant human erythropoietin and the anemia of cancer. Blood, 84, 9971004.
  • Strauss, H.G., Haensgen, G., Dunst, J., Hayward, C.R.W., Burgers, H.U., Scherhag, A. & Koelbl, H. (2008) Effects of anemia correction with epoetin beta in patients receiving radiochemotherapy for advanced cervical cancer. International Journal of Gynecological Cancer, 18, 515524.
  • Stuben, G., Thews, O., Pottgen, C., Knuhmann, K., Vaupel, P. & Stuschke, M. (2001) Recombinant human erythropoietin increases the radiosensitivity of xenografted human tumours in anaemic nude mice. Journal of Cancer Research and Clinical Oncology, 127, 346350.
  • Thews, O., Koenig, R., Kelleher, D.K., Kutzner, J. & Vaupel, P. (1998) Enhanced radiosensitivity in experimental tumours following erythropoietin treatment of chemotherapy-induced anaemia. British Journal of Cancer, 78, 752756.
  • Thews, O., Kelleher, D.K. & Vaupel, P. (2001) Erythropoietin restores the anemia-induced reduction in cyclophosphamide cytotoxicity in rat tumors. Cancer Research, 61, 13581361.
  • Tilbrook, P.A. & Klinken, S.P. (1999) The erythropoietin receptor. International Journal of Biochemistry and Cell Biology, 31, 10011005.
  • Toth, C., Martinez, J.A., Liu, W.Q., Diggle, J., Guo, G.F., Ramji, N., Mi, R., Hoke, A. & Zochodne, D.W. (2008) Local erythropoietin signaling enhances regeneration in peripheral axons. Neuroscience, 154, 767783.
  • Tramontano, A.F., Muniyappa, R., Black, A.D., Blendea, M.C., Cohen, I., Deng, L., Sowers, J.R., Cutaia, M.V. & El-Sherif, N. (2003) Erythropoietin protects cardiac myocytes from hypoxia-induced apoptosis through an Akt-dependent pathway. Biochemical and Biophysical Research Communications, 308, 990994.
  • Um, M. & Lodish, H.F. (2006) Antiapoptotic effects of erythropoietin in differentiated neuroblastoma SH-SY5Y cells require activation of both the STAT-5 and AKT signaling pathways. Journal of Biological Chemistry, 281, 56485656.
  • Um, M., Gross, A.W. & Lodish, H.F. (2007) A “classical” homodimeric erythropoietin receptor is essential for the antiapoptotic effects of erythropoietin on differentiated neuroblastoma SH-SY5Y and pheochromocytoma PC-12 cells. Cellular Signalling, 19, 634645.
  • Vansteenkiste, J., Pirker, R., Massuti, B., Barata, F., Font, A., Fiegl, M., Siena, S., Gateley, J., Tomita, D., Colowick, A.B. & Musil, J. (2002) Double-blind, placebo-controlled, randomized phase III trial of darbepoetin alfa in lung cancer patients receiving chemotherapy. Journal of the National Cancer Institute, 94, 12111220.
  • Watanabe, D., Suzuma, K., Matsui, S., Kurimoto, M., Kiryu, J., Kita, M., Suzuma, I., Ohashi, H., Ojima, T., Murakami, T., Kobayashi, T., Masuda, S., Nagao, M., Yoshimura, N. & Takagi, H. (2005) Erythropoietin as a retinal angiogenic factor in proliferative diabetic retinopathy. New England Journal of Medicine, 353, 782792.
  • Westenfelder, C. & Baranowski, R.L. (2000) Erythropoietin stimulates proliferation of human renal carcinoma cells. Kidney International, 58, 647657.
  • Wilkinson, P.M., Antonopoulos, M., Lahousen, M., Lind, M. & Kosmidis, P.for the EPO-INT-45 Study Group. (2006) Epoetin alfa in platinum-treated ovarian cancer patients: results of a multinational, multicentre, randomised trial. British Journal of Cancer, 94, 947954.
  • Witzig, T.E., Silberstein, P.T., Loprinzi, C.L., Sloan, J.A., Novotny, P.J., Mailliard, J.A., Rowland, K.M., Alberts, S.R., Krook, J.E., Levitt, R. & Morton, R.F. (2005) Phase III, randomized, double-blind study of epoetin alfa compared with placebo in anemic patients receiving chemotherapy. Journal of Clinical Oncology, 23, 26062617.
  • Won, Y.J., Yoo, J.Y., Lee, J.H., Hwang, S.J., Kim, D. & Hong, H.N. (2007) Erythropoietin is neuroprotective on GABAergic neurons against kainic acid-excitotoxicity in the rat spinal cell cultures. Brain Research, 1154, 3139.
  • Wright, J.R., Ung, Y.C., Julian, J.A., Pritchard, K.I., Whelan, T.J., Smith, C., Szechtman, B., Roa, W., Mulroy, L., Rudinskas, L., Gagnon, B., Okawara, G.S. & Levine, M.N. (2007) Randomized, double-blind, placebo-controlled trial of erythropoietin in non-small-cell lung cancer with disease-related anemia. Journal of Clinical Oncology, 25, 10271032.
  • Yasuda, Y., Masuda, S., Chikuma, M., Inoue, K., Nagao, M. & Sasaki, R. (1998) Estrogen-dependent production of erythropoietin in uterus and its implication in uterine angiogenesis. Journal of Biological Chemistry, 273, 2538125387.
  • Yasuda, Y., Musha, T., Tanaka, H., Fujita, Y., Fujita, H., Utsumi, H., Matsuo, T., Masuda, S., Nagao, M., Sasaki, R. & Nakamura, Y. (2001) Inhibition of erythropoietin signalling destroys xenografts of ovarian and uterine cancers in nude mice. British Journal of Cancer, 84, 836843.
  • Yasuda, Y., Fujita, Y., Matsuo, T., Koinuma, S., Hara, S., Tazaki, A., Onozaki, M., Hashimoto, M., Musha, T., Ogawa, K., Fujita, H., Nakamura, Y., Shiozaki, H. & Utsumi, H. (2003) Erythropoietin regulates tumour growth of human malignancies. Carcinogenesis, 24, 10211029.
  • Yu, X., Shacka, J.J., Eells, J.B., Suarez-Quian, C., Przygodzki, R.M., Beleslin-Cokic, B., Lin, C.S., Nikodem, V.M., Hempstead, B., Flanders, K.C., Costantini, F. & Noguchi, C.T. (2002) Erythropoietin receptor signalling is required for normal brain development. Development, 129, 505516.